About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

5 Must-Read Analyst Questions From Eli Lilly’s Q2 Earnings Call

By: StockStory

LLY Cover Image

Eli Lilly delivered above-consensus results in the second quarter, surpassing Wall Street’s revenue and non-GAAP profit expectations, yet the market response was notably negative. Management attributed the year-on-year growth to ongoing strength from key products such as Mounjaro and Zepbound, with robust demand in both diabetes and obesity markets. CEO David A. Ricks highlighted the positive clinical data from the ATTAIN-1 orforglipron trial and strong uptake of new products, but acknowledged headwinds tied to U.S. drug pricing reforms, competitive pressures, and changes in pharmacy benefit manager coverage. Ricks also pointed to continued investment in research and development and manufacturing expansion as central to supporting future growth.

Is now the time to buy LLY? Find out in our full research report (it’s free).

Eli Lilly (LLY) Q2 CY2025 Highlights:

  • Revenue: $15.56 billion vs analyst estimates of $14.76 billion (37.6% year-on-year growth, 5.4% beat)
  • Adjusted EPS: $6.31 vs analyst estimates of $5.59 (12.9% beat)
  • Adjusted EBITDA: $6.94 billion vs analyst estimates of $6.89 billion (44.6% margin, 0.7% beat)
  • The company lifted its revenue guidance for the full year to $61 billion at the midpoint from $59.5 billion, a 2.5% increase
  • Management raised its full-year Adjusted EPS guidance to $22.38 at the midpoint, a 3.9% increase
  • Operating Margin: 44.1%, up from 32.9% in the same quarter last year
  • Market Capitalization: $592.9 billion

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Eli Lilly’s Q2 Earnings Call

  • Christopher Thomas Schott (JPMorgan) asked how orforglipron’s weight loss profile stacks up against competitors; Kenneth L. Custer, Senior Vice President, emphasized the convenience and potential of an oral pill but acknowledged differences in efficacy versus injectables.
  • Seamus Christopher Fernandez (Guggenheim) pushed for detail on pricing strategy given increased competition and compounding; CEO David A. Ricks said Lilly will “price to value” and expects single-digit price erosion in chronic medications.
  • Timothy Minton Anderson (Bank of America) questioned the impact of upcoming Canadian generics on market dynamics; Ilya Yuffa, Executive Vice President, referenced strong Zepbound performance and cash pay market resilience but recognized ongoing competitive headwinds.
  • Stephen Michael Scala (TD Cowen) followed up on the CVS formulary exclusion’s impact; Yuffa explained that while prescription growth slowed, overall demand and share in other channels remained robust.
  • Akash Tewari (Jefferies) asked if Lilly would commit to net parity pricing between the U.S. and Europe; Ricks said the company seeks to rebalance global pricing but noted systemic challenges and the need for gradual structural change.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will focus on (1) the pace of regulatory submissions and readouts for orforglipron and other late-stage pipeline assets, (2) the continued expansion of manufacturing capacity and its effectiveness in meeting global demand, and (3) the evolving coverage landscape for anti-obesity drugs, particularly how employer and pharmacy benefit manager decisions affect prescription growth. Additional attention will be paid to developments in pricing negotiations and the company’s ability to navigate new competitive threats.

Eli Lilly currently trades at $662.86, down from $747.24 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.

Don’t let fear keep you from great opportunities and take a look at Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

More News

View More
Nike’s Turnaround: If the Shoe Fits, Buy It!
Via MarketBeat
Tickers NKE
NVIDIA Breaks Out to New Highs: What Comes Next?
Via MarketBeat
Topics Economy Stocks World Trade
Tickers CRWV META NVDA
Microsoft Stock Hits Stride in 2025—How Much More Can It Run?
Via MarketBeat
Topics Artificial Intelligence Retirement
Tickers MSFT
How Berkshire's OxyChem Buy Cements Its Long-Term Strength
Via MarketBeat
Tickers BRK BRK-A BRK-B OXY
Oklo Insiders Sell! Oh No! This Is Why Investors Shouldn’t Worry
Via MarketBeat
Tickers OKLO
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.